Takeda Discontinues Alisertib Phase 3 Trial in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
News
Takeda Pharmaceutical Company Limited recently announced its decision to discontinue a Phase 3 clinical trial that was evaluating the company’s drug candidate alisertib (MLN8237) as a treatment for patients suffering with ... Read more